Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 636514, 5 pages
http://dx.doi.org/10.1155/2014/636514
Review Article

MMSET: Role and Therapeutic Opportunities in Multiple Myeloma

1Cancer Science Institute of Singapore, National University of Singapore, 14 Medical Drive, Singapore 117599
2Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge Road, Singapore 119228
3Department of Haematology-Oncology, National University Cancer Institute of Singapore, National University Health System, Singapore 119228

Received 17 March 2014; Accepted 16 June 2014; Published 1 July 2014

Academic Editor: Dong Soon Lee

Copyright © 2014 Zhigang Xie and Wee Joo Chng. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Rodríguez-Paredes and M. Esteller, “Cancer epigenetics reaches mainstream oncology,” Nature Medicine, vol. 17, no. 3, pp. 330–339, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. M. A. Dawson and T. Kouzarides, “Cancer epigenetics: from mechanism to therapy,” Cell, vol. 150, no. 1, pp. 12–27, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. P. Angrand, F. Apiou, A. F. Stewart, B. Dutrillaux, R. Losson, and P. Chambon, “NSD3, a new SET domain-containing gene, maps to 8p12 and is amplified in human breast cancer cell lines,” Genomics, vol. 74, no. 1, pp. 79–88, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. I. Stec, T. J. Wright, G. J. van Ommen et al., “WHSC1, a 90 kb SET domain-containing gene, expressed in early development and homologous to a Drosophila dysmorphy gene maps in the Wolf-Hirschhorn syndrome critical region and is fused to IgH in t(4;14) multiple myeloma,” Human Molecular Genetics, vol. 7, pp. 1071–1082, 1998. View at Google Scholar
  5. N. Huang, E. vom Baur, J. Garnier et al., “Two distinct nuclear receptor interaction domains in NSD1, a novel SET protein that exhibits characteristics of both corepressors and coactivators,” The EMBO Journal, vol. 17, no. 12, pp. 3398–3412, 1998. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Chesi, E. Nardini, R. S. C. Lim, K. D. Smith, W. Michael Kuehl, and P. L. Bergsagel, “The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts,” Blood, vol. 92, no. 9, pp. 3025–3034, 1998. View at Google Scholar · View at Scopus
  7. C. G. Garlisi, A. S. Uss, H. Xiao et al., “A unique mRNA initiated within a middle intron of WHSC1/MMSET encodes a DNA binding protein that suppresses human IL-5 transcription,” American Journal of Respiratory Cell and Molecular Biology, vol. 24, no. 1, pp. 90–98, 2001. View at Publisher · View at Google Scholar · View at Scopus
  8. P. V. Peña, F. Davrazou, X. Shi et al., “Molecular mechanism of histone H3K4me3 recognition by plant homeodomain of ING2,” Nature, vol. 442, no. 7098, pp. 100–103, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Wu, H. Zeng, R. Lam et al., “Structural and histone binding ability characterizations of human PWWP domains,” PLoS ONE, vol. 6, no. 6, Article ID e18919, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. Z. Huang, H. Wu, S. Chuai et al., “NSD2 is recruited through its PHD domain to oncogenic gene loci to drive multiple myeloma,” Cancer Research, vol. 73, pp. 6277–6288, 2013. View at Publisher · View at Google Scholar
  11. M. Štros, D. Launholt, and K. D. Grasser, “The HMG-box: a versatile protein domain occurring in a wide variety of DNA-binding proteins,” Cellular and Molecular Life Sciences, vol. 64, no. 19-20, pp. 2590–2606, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. J. J. Keats, C. A. Maxwell, B. J. Taylor et al., “Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients,” Blood, vol. 105, no. 10, pp. 4060–4069, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Lauring, A. M. Abukhdeir, H. Konishi et al., “The multiple myeloma-associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity,” Blood, vol. 111, no. 2, pp. 856–864, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. P. L. Bergsagel and W. M. Kuehl, “Molecular pathogenesis and a consequent classification of multiple myeloma,” Journal of Clinical Oncology, vol. 23, no. 26, pp. 6333–6338, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. P. L. Bergsagel and W. M. Kuehl, “Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma,” Immunological Reviews, vol. 194, pp. 96–104, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. J. J. Keats, T. Reiman, A. R. Belch, and L. M. Pilarski, “Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma,” Leukemia and Lymphoma, vol. 47, no. 11, pp. 2289–2300, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. J. J. Keats, T. Reiman, C. A. Maxwell et al., “In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression,” Blood, vol. 101, no. 4, pp. 1520–1529, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Santra, F. Zhan, E. Tian, B. Barlogie, and J. Shaughnessy Jr., “A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript,” Blood, vol. 101, no. 6, pp. 2374–2376, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Marango, M. Shimoyama, H. Nishio et al., “The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor,” Blood, vol. 111, no. 6, pp. 3145–3154, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. J. L. R. Brito, B. Walker, M. Jenner et al., “MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells,” Haematologica, vol. 94, no. 1, pp. 78–86, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. E. Martinez-Garcia, R. Popovic, D. Min et al., “The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells,” Blood, vol. 117, no. 1, pp. 211–220, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. A. J. Kuo, P. Cheung, K. Chen et al., “NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming,” Molecular Cell, vol. 44, no. 4, pp. 609–620, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Kassambara, B. Klein, and J. Moreaux, “MMSET is overexpressed in cancers: link with tumor aggressiveness,” Biochemical and Biophysical Research Communications, vol. 379, no. 4, pp. 840–845, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Morishita and E. di Luccio, “Cancers and the NSD family of histone lysine methyltransferases,” Biochimica et Biophysica Acta, vol. 1816, no. 2, pp. 158–163, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. X. J. Sun, J. Wei, X. Y. Wu et al., “Identification and characterization of a novel human histone H3 lysine 36-specific methyltransferase,” Journal of Biological Chemistry, vol. 280, no. 42, pp. 35261–35271, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. H. B. Kang, Y. Choi, J. M. Lee et al., “The histone methyltransferase, NSD2, enhances androgen receptor-mediated transcription,” FEBS Letters, vol. 583, no. 12, pp. 1880–1886, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Y. Kim, J. K. Hae, N. W. Choe et al., “Multiple myeloma-related WHSC1/MMSET isoform RE-IIBP is a histone methyltransferase with transcriptional repression activity,” Molecular and Cellular Biology, vol. 28, no. 6, pp. 2023–2034, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. Y. Li, P. Trojer, C. Xu et al., “The target of the NSD family of histone lysine methyltransferases depends on the nature of the substrate,” The Journal of Biological Chemistry, vol. 284, no. 49, pp. 34283–34295, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. K. Nimura, K. Ura, H. Shiratori et al., “A histone H3 lysine 36 trimethyltransferase links Nkx2-5 to Wolf-Hirschhorn syndrome,” Nature, vol. 460, no. 7252, pp. 287–291, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. H. Pei, L. Zhang, K. Luo et al., “MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites,” Nature, vol. 470, no. 7332, pp. 124–128, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. K. Todoerti, D. Ronchetti, L. Agnelli et al., “Transcription repression activity is associated with the type I isoform of the MMSET gene involved in t(4;14) in multiple myeloma,” British Journal of Haematology, vol. 131, no. 2, pp. 214–218, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. O. Binda, “On your histone mark, SET, methylate!,” Epigenetics, vol. 8, no. 5, pp. 457–463, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. D. J. Min, T. Ezponda, M. K. Kim et al., “MMSET stimulates myeloma cell growth through microRNA-mediated modulation of c-MYC,” Leukemia, vol. 27, no. 3, pp. 686–694, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. Z. Xie, J. Gunaratne, L. L. Cheong et al., “Plasma membrane proteomics identifies biomarkers associated with MMSET overexpression in T(4;14) multiple myeloma,” Oncotarget, vol. 4, no. 7, pp. 1008–1018, 2013. View at Google Scholar
  35. G. Toyokawa, H. Cho, K. Masuda et al., “Histone lysine methyltransferase Wolf-Hirschhorn syndrome candidate 1 is involved in human carcinogenesis through regulation of the WNT pathway,” Neoplasia, vol. 13, no. 10, pp. 887–898, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. P. Yang, L. Guo, Z. J. Duan et al., “Histone methyltransferase NSD2/MMSET mediates constitutive NF-kb signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop,” Molecular and Cellular Biology, vol. 32, no. 15, pp. 3121–3131, 2012. View at Publisher · View at Google Scholar · View at Scopus
  37. T. Ezponda, R. Popovic, M. Y. Shah et al., “The histone methyltransferase MMSET/WHSC1 activates TWIST1 to promote an epithelial-mesenchymal transition and invasive properties of prostate cancer,” Oncogene, vol. 32, no. 23, pp. 2882–2890, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. F. Cao, E. C. Townsend, H. Karatas et al., “Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia,” Molecular Cell, vol. 53, no. 2, pp. 247–261, 2014. View at Publisher · View at Google Scholar
  39. E. M. Smith, K. Boyd, and F. E. Davies, “The potential role of epigenetic therapy in multiple myeloma,” British Journal of Haematology, vol. 148, no. 5, pp. 702–713, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. D. H. Kim and J. J. Rossi, “Strategies for silencing human disease using RNA interference,” Nature Reviews Genetics, vol. 8, no. 3, pp. 173–184, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. K. F. Pirollo and E. H. Chang, “Targeted delivery of small interfering RNA: approaching effective cancer therapies,” Cancer Research, vol. 68, no. 5, pp. 1247–1250, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. S. V. Rajkumar, “Treatment of multiple myeloma,” Nature Reviews Clinical Oncology, vol. 8, no. 8, pp. 479–491, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. M. V. Mateos, E. M. Ocio, and J. F. San Miguel, “Novel generation of agents with proven clinical activity in multiple myeloma,” Seminars in Oncology, vol. 40, pp. 618–633, 2013. View at Google Scholar